Please join the New York/New Jersey AIDS Education and Training Center and the U.S. Department of Health and Human Services in Region II as we host the Hepatitis C in 2014 Webinar Series for clinicians focusing on the newly released Recommendations for Testing, Managing, and Treating Hepatitis C.

This third webinar in the three-part series will focus on the recommendations for the treatment experienced patient and for treating Hepatitis C and HIV Co-infection. The webinar is intended for clinical providers. 

 The one-hour webinar will take place on Wednesday, April 30, 2014 at 12:00 - 1:00 EST.

Webinar Presenters
John J. Faragon, PharmD, BCPS, AAHIV-P
Douglas G. Fish, MD, AAHIVS

Presenter Bio

About the NY/NJ AIDS Education and Training Center

 

Objectives

1. Discuss the role of HCV direct acting antivirals (DAA) in patients co-infected with HIV and HCV and those that are treatment experienced.
2. List the preferred regimens provided in the new AASLD/IDSA guidelines for managing HCV infection in co-infection and in treatment experienced patients. 
3. Using clinical case scenarios, apply principles and recommendations in new AASLD/IDSA guidelines to real cases. 
4. Review common drug interactions likely to occur with DAAs and provide online resources to assist providers in patient care.  

Registration  

To join the webinar please follow these two steps:
1. Please visit the Participant Information Form and submit requested
    information
2. Click below on "Register Now!" to complete webinar registration

Register Now! 

This webinar series was made possible in part by AETC grant award # H4AHA00071 from the HIV/AIDS Bureau of the Health Resources Services Administration (HRSA), U.S. Department of Health and Human Services (HHS).  NY/NJ AETC is one of 11 regional and 3 national AIDS Education and Training Center (AETC) that strengthens the capacity of health care professionals to care for people living with HIV/AIDS through training and technical assistance.  The information presented here is the consensus of HIV/AIDS specialists and does not necessarily represent the official views of HRSA/HAB.